- Larimar Therapeutics Inc (NASDAQ:LRMR) following a recent Type C Meeting.
- The company plans to submit a complete response to the in Q3.
- In conjunction with the complete response, Larimar is proposing as CTI-1601's next trial a Phase 2, four-week dose exploration study in Friedreich's Ataxia starting at the lower dose levels tested in the company's Phase 1 multiple-ascending dose trial.
- This study will provide additional data on safety & tolerability and whether lower doses for longer periods can increase frataxin levels while maintaining acceptable exposures.
- Related: .
- Data from Phase 1 trials showed that 50 or 100 mg of CTI-1601, administered daily for at least seven days, resulted in frataxin levels in peripheral tissues (buccal cells).
- Cohort 1 of the MAD trial evaluated a 25 mg dose and explored a daily dosing regimen for only four days.
- Larimar ended the June quarter with a cash balance of $54.9 million, which provides a projected cash runway through Q3 of 2023.
- Price Action: LRMR shares are up 14.64% at $2.27 during the premarket session on the last check Friday.
Information, charts or examples are for illustration and educational purposes only and not for individualized investment management This message contains commercial elements, such as advertising. We only send these offers to those who have opted in to our newsletter. Past performance is not indicative of future results. For these reasons we strongly suggest trading in a DEMO/Simulated account. The information provided by us is for educational and informational purposes only. We make no representations or warranties concerning the products, practices or procedures of any company or entity mentioned or recommended and have not determined if the statements and opinions of the advertiser are accurate, correct or truthful. If you use, act upon or make decisions in reliance on information contained or any external source linked within it, you do so at your own peril and agree to hold us, our officers, directors, shareholders, affiliates and agents without fault.